Beyond amyloid: A diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias

Rachel F. Lane; Diana W. Shineman; Howard M. Fillit

doi:10.1186/alzrt99

Beyond amyloid: A diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias

Rachel F. Lane, Diana W. Shineman, Howard M. Fillit

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochondrial dysfunction and perturbed calcium homeostasis have been identified as key events leading to neuronal loss during neurodegeneration. Evidence for 'druggable' targets for each of these key mechanisms was presented by the Alzheimer's Drug Discovery Foundation-funded investigators at the 12th International Conference on Alzheimer's Drug Discovery, Jersey City, NJ, 26-27 September 2011 http://www.worldeventsforum.com/addf/addrugdiscovery.

Original language	English
Article number	36
Journal	Alzheimer's Research and Therapy
Volume	3
Issue number	6
DOIs	https://doi.org/10.1186/alzrt99
State	Published - 2011
Externally published	Yes

Access to Document

10.1186/alzrt99

Cite this

@article{a9b0d4f794d8412c8ce7f3e41c46c509,

title = "Beyond amyloid: A diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias",

abstract = "Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochondrial dysfunction and perturbed calcium homeostasis have been identified as key events leading to neuronal loss during neurodegeneration. Evidence for 'druggable' targets for each of these key mechanisms was presented by the Alzheimer's Drug Discovery Foundation-funded investigators at the 12th International Conference on Alzheimer's Drug Discovery, Jersey City, NJ, 26-27 September 2011 http://www.worldeventsforum.com/addf/addrugdiscovery.",

author = "Lane, {Rachel F.} and Shineman, {Diana W.} and Fillit, {Howard M.}",

note = "Funding Information: A wide variety of novel therapeutic strategies were presented at the 12th International Conference on Alzheimer{\textquoteright}s Drug discovery hosted by the Alzheimer{\textquoteright}s Drug Discovery Foundation (ADDF). Th is report highlights novel strategies funded by the ADDF that are progressing through the drug development pipeline (Figure 1).",

year = "2011",

doi = "10.1186/alzrt99",

language = "English",

volume = "3",

journal = "Alzheimer's Research and Therapy",

issn = "1758-9193",

publisher = "BioMed Central Ltd.",

number = "6",

}

TY - JOUR

T1 - Beyond amyloid

T2 - A diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias

AU - Lane, Rachel F.

AU - Shineman, Diana W.

AU - Fillit, Howard M.

N1 - Funding Information: A wide variety of novel therapeutic strategies were presented at the 12th International Conference on Alzheimer’s Drug discovery hosted by the Alzheimer’s Drug Discovery Foundation (ADDF). Th is report highlights novel strategies funded by the ADDF that are progressing through the drug development pipeline (Figure 1).

PY - 2011

Y1 - 2011

N2 - Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochondrial dysfunction and perturbed calcium homeostasis have been identified as key events leading to neuronal loss during neurodegeneration. Evidence for 'druggable' targets for each of these key mechanisms was presented by the Alzheimer's Drug Discovery Foundation-funded investigators at the 12th International Conference on Alzheimer's Drug Discovery, Jersey City, NJ, 26-27 September 2011 http://www.worldeventsforum.com/addf/addrugdiscovery.

AB - Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochondrial dysfunction and perturbed calcium homeostasis have been identified as key events leading to neuronal loss during neurodegeneration. Evidence for 'druggable' targets for each of these key mechanisms was presented by the Alzheimer's Drug Discovery Foundation-funded investigators at the 12th International Conference on Alzheimer's Drug Discovery, Jersey City, NJ, 26-27 September 2011 http://www.worldeventsforum.com/addf/addrugdiscovery.

UR - http://www.scopus.com/inward/record.url?scp=84855590508&partnerID=8YFLogxK

U2 - 10.1186/alzrt99

DO - 10.1186/alzrt99

M3 - Article

AN - SCOPUS:84855590508

SN - 1758-9193

VL - 3

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

IS - 6

M1 - 36

ER -

Beyond amyloid: A diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias

Abstract

Access to Document

Fingerprint

Cite this